Our findings suggest then that TCF7L2 mutations or single-nucleotide polymorphism variants might modify both the degree of ischaemic myelin damage in patients with type 2 diabetes and their ability to remyelinate. This evidence concerns the gene TCF7L2 and type 2 diabetes mellitus.